5(R)-hydroxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one | 82796-40-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 5(R)-hydroxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one
• 英文别名: (R)-3-[4-(methylthio)phenyl]-2-oxo-5-(hydroxymethyl)oxazolidine；(5R)-5-(Hydroxymethyl)-3-[4-(methylsulfanyl)phenyl]-1,3-oxazolidin-2-one；(5R)-5-(hydroxymethyl)-3-(4-methylsulfanylphenyl)-1,3-oxazolidin-2-one
• CAS: 82796-40-5
• 化学式: C₁₁H₁₃NO₃S
• 分子量: 239.295
• InChiKey: QPXCTJMLKKNYGA-SECBINFHSA-N

物化性质

• 沸点：
  408.5±28.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  75.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5(R)-hydroxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one 在 吡啶 、 1,3-丙二硫醇 、 sodium hydroxide 、 sodium azide 、 18-冠醚-6 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.5h， 生成 N-[3-(4-甲基亚磺酰苯基)-2-氧代-1,3-恶唑烷-5-基甲基]乙酰胺
  参考文献：
  名称：

  Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The B group

  摘要：

  The synthesis and structure/activity studies of the effect of varying the "B" group in a series of oxazolidinone antibacterials (I) are described. Two synthetic routes were used: (1) alkylation of aniline with glycidol followed by dialkyl carbonate heterocyclization to afford I (A = H, B = OH), whose arene ring was further elaborated by using electrophilic aromatic substitution methodology; (2) cycloaddition of substituted aryl isocyanates with epoxides to give A and B with a variety of values. I with B = OH or Br were converted to other "B" functionalities by using SN2 methodology. Antibacterial evaluation of compounds I with A = acetyl, isopropyl, methylthio, methylsulfinyl, methylsulfonyl, and sulfonamido and a variety of different "B" groups against Staphylococcus aureus and Enterococcus faecalis concluded that the compounds with B = aminoacyl, and particularly acetamido, were the most active of those examined in each A series, possessing MICs in the range of 0.5-4 micrograms/mL for the most active compounds described.

  DOI：

  10.1021/jm00128a003
• 作为产物：
  描述：

  异氰酸- 4(甲硫基)苯酯 在 三正丁基氧化磷 、 sodium methylate 、 lithium bromide 作用下， 以 甲醇 、 xylene 为溶剂， 反应 4.0h， 生成 5(R)-hydroxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one
  参考文献：
  名称：

  Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The B group

  摘要：

  The synthesis and structure/activity studies of the effect of varying the "B" group in a series of oxazolidinone antibacterials (I) are described. Two synthetic routes were used: (1) alkylation of aniline with glycidol followed by dialkyl carbonate heterocyclization to afford I (A = H, B = OH), whose arene ring was further elaborated by using electrophilic aromatic substitution methodology; (2) cycloaddition of substituted aryl isocyanates with epoxides to give A and B with a variety of values. I with B = OH or Br were converted to other "B" functionalities by using SN2 methodology. Antibacterial evaluation of compounds I with A = acetyl, isopropyl, methylthio, methylsulfinyl, methylsulfonyl, and sulfonamido and a variety of different "B" groups against Staphylococcus aureus and Enterococcus faecalis concluded that the compounds with B = aminoacyl, and particularly acetamido, were the most active of those examined in each A series, possessing MICs in the range of 0.5-4 micrograms/mL for the most active compounds described.

  DOI：

  10.1021/jm00128a003

文献信息

• Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：Syngenta Limited

  公开号：US20030144263A1

  公开（公告）日：2003-07-31

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein, for example, X is —O— or —S—; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  式(I)的化合物，或其药学上可接受的盐，或其体内可水解的酯， 其中，例如，X为—O—或—S—； HET是一个可选择的取代的C-连接的含有2到4个异原子（独立选择自N、O和S）的5元杂芳环； Q从Q1和Q2中选择 R2和R3独立地为氢或氟； T从一系列基团中选择，例如，一个N-连接的（完全不饱和的）5元杂芳环系统或式(TC5)的基团： 其中Rc是，例如，R13CO—，R13SO2—或R13CS—； 其中R13是，例如，可选择的取代的(1-10C)烷基或R14C(O)O(1-6C)烷基 其中R14是可选择的取代的(1-10C)烷基；这些化合物可用作抗菌剂；并描述了其制备方法和含有它们的药物组合物。
• Oxazolidinone compounds and pharmaceutical compositions containing them
  申请人：AstraZeneca AB

  公开号：EP1357122A2

  公开（公告）日：2003-10-29

  The current invention provides an in-vivo hydrolysable ester of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof; wherein X is -O- or -S-; HET is an optionally substituted C-linked 6-membered heteroaryl ring containing 1 or 2 N; Q is Q1 and T is for example:

  当前发明提供了化合物(I)的体内可水解酯或其药用可接受的盐；其中X为-O-或-S-；HET为含有1或2个N的可选择取代的C-连接的6元杂环芳基环；Q为Q1，T为例如：
• Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
  申请人：E. I. Du Pont de Nemours and Company

  公开号：US04705799A1

  公开（公告）日：1987-11-10

  Novel aminomethyl oxooxazolidinyl benzene derivatives, including the sulfides, sulfoxides, sulfones and sulfonamides, such as (l)-N-[3-[4-(methylsulfinyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, possess useful antibacterial activity.

  新型氨甲基氧噁唑啉基苯衍生物，包括硫醚、亚硫醚、磺酰和磺酰胺衍生物，如（l）-N-[3-[4-(甲基亚磺基)苯基]-2-氧噁唑啉-5-基甲基]乙酰胺，具有有用的抗菌活性。
• FUGITT, ROBERT BENSON;LUCKENBAUGH, RAYMOND WILSON
  作者：FUGITT, ROBERT BENSON、LUCKENBAUGH, RAYMOND WILSON

  DOI：——

  日期：——
• OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：AstraZeneca AB

  公开号：EP1082322A2

  公开（公告）日：2001-03-14